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Edited by Takashi GojoboriAbstract Human hepatocellular carcinoma (HCC) is one of the
most common tumors worldwide, in which the genetic mecha-
nisms of oncogenesis are still unclear. To investigate whether
the genomic DNA copy number alterations may contribute to
primary HCC, the cDNA microarray-based comparative geno-
mic hybridization (CGH) analysis was here performed in 41 pri-
mary HCC infected by hepatitis B virus and 12 HCC cell lines.
The resulting data showed that, on average, 7.25% of genome-
wide DNA copy numbers was signiﬁcantly altered in those
samples (4.61 ± 2.49% gained and 2.64 ± 1.78% lost). Gains
involving 1q, 6p, 8q and 9p were frequently observed in these
cases; and whilst, losses involving Ip, 16q and 19p occurred in
most patients. To address the correlation between the alteration
of genomic DNA copy numbers and transcriptional expression,
the same cDNA microarray was further applied in 20 HCC spec-
imens and all available cell lines to ﬁgure out the gene expression
proﬁles of those samples. Interestingly, the genomic DNA copy
number alterations of most genes appeared not to be in generally
parallel with the corresponding transcriptional expression. How-
ever, the transcriptional deregulation of a few genes, such as
osteopontin (SPP1), transgelin 2 (TAGLN2) and PEG10, could
be ascribed partially to their genomic aberrations, although the
many alternative mechanisms could be involved in the deregula-
tion of these genes. In general, this work would provide new in-
sights into the genetic mechanisms in hepatocarcinogenesis
associated with hepatitis B virus through the comprehensive sur-
vey on correlation between genomic DNA copy number altera-
tions and transcriptional expression.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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expression1. Introduction
Hepatocellular carcinoma (HCC), a highly malignant tumor
in the world, is one of the most frequent tumors in Asia,
including China and Japan, and sub-Saharan Africa, in which
the susceptible factors, such as the infection of hepatitis B virus*Corresponding author. Fax: +86 21 50800402.
E-mail address: hanzg@chgc.sh.cn (Z.-G. Han).
0014-5793/$32.00  2006 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2006.05.032(HBV) and hepatitis C virus (HCV), chronic exposure to Aﬂa-
toxin B1 (AFB1) and alcoholic cirrhosis, have been well iden-
tiﬁed and characterized [1]. The previous studies indicated that
the genetic abnormality of some genes, including potential
oncogenes and tumor suppressor genes, could be involved in
hepatocarcinogenesis. However, the genetic alterations were
only found in few patients with HCC, and whereas, the genetic
mechanisms of most HCC are still not completely elucidated.
As we know, chromosomal instability, including gain or loss
of the region-speciﬁc genomic DNA copy number, is associ-
ated with tumor development and progression. These chromo-
somal regions with DNA ampliﬁcation often harbor
oncogenes, whereas tumor repressor genes are commonly
localized on certain regions with allelic deletion. To identify
the chromosomal regions that may be crucial to hepatocarci-
nogenesis, a number of approaches had been employed to de-
tect the genomic alterations in HCC samples, including
cytogenetics, interphase ﬂuorescence in situ hybridization
(FISH), Southern blot analysis, the conventional metaphase-
based comparative genomic hybridization (CGH) and geno-
typing analyses [2–4]. These data provided large numbers of
valuable information, in which DNA ampliﬁcation on certain
chromosomal regions involving 1q, 8q and 17q, as well as alle-
lic deletion on the chromosomes 1p, 4q, 5q, 6q, 8p, 9p, 13q,
16p, 16q, and 17p were reported in more than 30% of HCC
samples [3]. Some known or candidate oncogenes and tumor
suppressor genes on these regions, such as L-myc on 1p35-
36, TERC on 3q26, APC on 5q21, SMAD5 on 5q31, MET
on 7q31, c-MYC/PTK2/EIF3S3 on 8q23-q24, p16INK4A/
p19ARF on 9p21, PTEN on 10q23, IGF2/cyclin D1/FGF3/
FGF4/EMS1 on 11q13, SAS/CDK4 on 12q13-q14, Rb-1 on
13q14, Axin-1/SOCS-1 on 16p13.3, E-cadherin on 16q22.1
and p53 on 17p13 [2,5], could be considered to be involved
in hepatocarcinogenesis. However, these approaches only pro-
vided the limited information on genomic DNA copy number
changes in tumors due to the lower resolution, although the
conventional metaphase-based CGH has been used for
addressing the DNA copy number changes of HCC. In gen-
eral, the conventional CGH assay only detected the genomic
regions with greater than 5–10 Mb for deletions and 2 Mb
for ampliﬁcation [6–8], but it was very diﬃcult to identify
the genomic alterations within less than 1 Mb that may
contains numerous genes. To circumvent this limitation,blished by Elsevier B.V. All rights reserved.
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detection of the DNA copy number aberrations in some dis-
eases [9–12], in particular cancers [7,13]. The microarray-based
CGH has been proven to be a speciﬁc, sensitive, and fast tech-
nique, with considerable advantages compared to other meth-
ods used for the high-resolution detection of DNA copy
number aberration.
In addition, it is controversial for whether the genomic DNA
copy number aberrations may alter gene expression in some
tumors. The previous studies revealed that the DNA copy
number alterations can lead directly to global deregulation
of gene expression in breast tumors [14,15], pancreatic cancers
[16,17], an immortalized prostate epithelial cell line [18], and
artiﬁcial chromosome trisomies [19], which could contribute
to the development or progression of cancers. In contrast, only
4% of genes within these ampliﬁed regions were found to be
highly expressed in metastatic colon tumors [20].
To ﬁgure out the genome-wide pattern of DNA copy num-
ber alterations with high-resolution in HCC, herein, the home-
made cDNA microarray was ﬁrst employed to detect theTable 1
Clinicopathological information of 41 test samples
No. Patients Gender Age HBV HCV AFP of
serum
(ng/ml)
Tumor
size (mm)
T
n
C01 03-10C Female 55 +  680 4 1
C02 03-12C Male 25 +  1756 3.8 2
C03 03-13C Male 58 +  2 16 1
C04 03-14C Female 71 +  400 11 1
C05 03-15C Male 67 +  6 7 1
C06 03-16C Male 48 +  3 15 1
C07 03-17C Male 63 +  1834 3 1
C08 03-18C Male 38 +  35 2.4 1
C09 03-19C Male 48 +  5 2.7 1
C10 03-21C Male 71 +  7 10 1
C11 03-22C Male 53 +  55 2 1
C12 03-23C Male 39 +  1889 10 1
C13 03-24C Male 45 +  347 2 2
C14 03-25C Male 40 +  1885 5 1
C15 03-29C Female 42 +  698 8.5 1
C16 03-30C Female 39 +  2 5.8 1
C17 ZS-21C Male 51 +  89 7 1
C18 ZS-23c Male 52 +  421 2.8 1
C19 ZS-24c Male 58 +  72 7.5 1
C20 ZS-25C Male 37 +  11105 3 1
C21 ZS-26c Male 42 +  1175 8.5 2
C22 ZS-27c Male 40 +  10 11.5 1
C23 ZS-30C Female 59 +  13660 3.5 3
C24 ZS-33c Male 72 +  320 7 1
C25 ZS-34c Male 62 +  3535 11 1
C26 ZS-35C Male 54 +  29875 10 1
C27 ZS-36C Male 53 +  4 3.5 1
C28 ZS-37C Male 71 + + 329 3.2 1
C29 ZS-38c Male 59 +  157 1.6 1
C30 ZS-39C Female 30 +  573 6 1
C31 ZS-43c Male 35 +  26 6.5 1
C32 50C Male 41 +  36.9 4.5 1
C33 51C Female 47 +  1.61 4.5 1
C34 52C Male 41 +  15.2 3.5 1
C35 53C Male 54 +  1234 3 1
C36 40C Female 67 +  35 8.5 1
C37 41C Male 57 +  5 9.5 1
C38 D06 Male 49 +  9 3.5 1
C39 G09 Female 48 +  60 7 1
C40 XUF08 Male 38 +  1100 11 1
C41 E07C Male 45 +  300 10 1
HCC, hepatocellular carcinoma.genomic DNA copy number changes in 41 HCC specimens,
6 adjacent non-cancerous livers, and 12 HCC cell lines by
the array-based CGH approach. Furthermore, to address the
correlation between the genomic abnormality and transcrip-
tional expression of those genes within the aberrational regions
in HCC, the gene expression proﬁles were performed on the
same 20 samples with the same cDNA microarray. Those data
would provide comprehensive resources for profound under-
standing of the genetic mechanisms involved in hepatocarcino-
genesis.2. Materials and methods
2.1. Tissue specimens
Tumor samples were obtained from 41 patients with HCC (Table 1)
who underwent surgical resection of their diseases and were informed
consent before operation on their livers. The primary tumors speci-
mens were immediately frozen at 80 C. Both paired tumor and adja-
cent non-tumor tissues were sampled respectively, with approximate
1 cm3 size of each specimen. All tumors and the adjacent noncancerousumor
umber
Lymphatic
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Cellular
type
Pathological
staging
Clinical
staging
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mens in this presenting work were grouped as the diﬀerentiation grades
II–III according to the Edmondson grading system.
2.2. Liver cancer cell lines
Twelve liver tumor-derived cell lines (Bel-7402, PLC, MHCC-H,
HepG2, QGY-7703, Hep3B, MHCC-L, YY-8103, Bel-7405, QGY-
7701, SSMC-7721, and Focus) were used in this study. All of these cell
lines were grown under standard cell culture conditions in the follow-
ing media: minimum essential medium Eagle (Sigma, Dorset, UK) sup-
plemented with 10% fetal bovine serum (Life Technologies), 1% L-
glutamine (L-glut) and 1% non-essential amino acids (NEAA) in a
5% CO2-humidiﬁed chamber.
2.3. Extraction of genomic DNA
In this experiments, genomic DNA was extracted from all available
HCC specimens, HCC cell lines and ﬁve adjacent non-cancerous livers
using the Dneasy Tissue kit (Qiagen, USA) according to the manufac-
turer’s recommendation. Mixed genomic DNA of lymphocytes ob-
tained from healthy individuals (one male and one female) was used
as diploid reference.
2.4. Extraction of total RNA
HCC specimens and the corresponding non-cancerous livers were
whetted to powder in the mortar with existing liquid nitrogen, and then
poured into one centrifugal tube and homogenized in TRIzol solution
(1 ml/50–100 mg). After these homogenates were incubated for 15 min
at room temperature, chloroform (0.2 ml of per ml of TRIzol reagent)
was added to the homogenates and then vigorously agitated for 5 min.
The inorganic phase was separated by centrifugation at 12000 · g for
20 min at 4 C. RNA was precipitated in the presence of 0.2 ml of chlo-
roform added as per ml of TRIZol reagent, and then centrifuged at
10000 · g for 15 min at 4 C. RNA pellets were washed with 75% eth-
anol and then dissolved in diethyl pyrocarbonate (DEPC)-treated
H2O. The selection of poly
+(A) RNA from total RNA was performed
by using oligo (dT) according to the manufacturer’s recommendation
(Qiagen, Chatsworth, CA). Total RNA concentration and quantity
were assessed by absorbency at 260 nm using a DNA/Protein Analyzer
(DU 530, Beckman, USA).
2.5. Microarray-based comparative genomic hybridization (CGH)
The homemade cDNA microarray used in this present work was
consisted of 13824 genes/ESTs, which these cDNA clones were derived
from our previous HCC and liver cDNA library [21] and their PCR
products were printed on glass slides for microarray-based CGH as de-
scribed earlier [10,22,23]. For each labelling, genomic DNA (2 lg) was
ﬁrst digested by DpnII andHaeIII (New England Biolabs) respectively,
and then 1 lg of each DNA sample digested, respectively, by both en-
zymes was equally mixed. The mixture (2 lg) was labelled using ran-
dom-primer (TaKaRa DNA Labelling Kit) in a 25 ll reaction,
including dATP, dGTP and dTTP of 120 lM each as well as dCTP,
Cy5-dCTP (for tested specimen) or Cy3-dCTP (for reference sample)
of 60 lM each, and then incubated at 37 C for 2 hours. For two-color
array hybridization, the puriﬁed probes labelled by Cy5 and Cy3
respectively were equally mixed to in one new eppendorf tube, and
then human Cot-1 DNA (50 lg; Gibco BRL), yeast tRNA (50 lg; Gib-
co BRL) and poly(dA-dT) (20 lg; Sigma) are added. After drying the
mixture, the debris was diluted to solution containing 3.4· SSC and
0.3% SDS in a 40 ll ﬁnal volume. Following denaturation (100 C
for 1.5 min) and pre-anneal (37 C for 60 min), the probes were hybrid-
ized to the microarray under a glass coverslip at 42 C for 16–20 h, and
then the array was washed in 0.1· SSC, 0.2% SDS (55 C for 10 min),
followed by 1· SSC, 0.2% SDS at 55 C for 10 min, and ﬁnally washed
in 0.1· SSC. The signal intensity of hybridization was measured by
confocal ﬂuorescence microscopy (Agilent Technologies, Palo Alto,
CA).2.6. Gene expression proﬁle analysis
The cDNA microarray analysis for gene expression was performed
as previously described [24]. Here, to ﬁgure out the diﬀerential display
of gene expression between those paired of HCC and adjacent non-tu-
mor tissues, the RNAs from HCC samples were used as test groups la-
belled by Cy5, whereas the corresponding non-tumor livers were servedas the reference labelled by Cy3. For 12 HCC cell lines, the equally
mixed RNA obtained from these 12 HCC cell lines was used as refer-
ence, whereas RNA sample obtained from a given cell line was served
as tested one.
2.7. Image acquisition and data analysis
Hybridized array slides were scanned by confocal ﬂuorescence
microscopy as the manufacture’s instruction (Agilent Technologies).
The ﬂuorescence ratios were calculated after background subtraction
(the median ﬂuorescence signal of non-target pixels was served as
background) using Agilent G2567AA Feature Extraction Software
according to the manufacturer’s instructions. The test (Cy5)/reference
(Cy3) ratio was determined automatically for each sample, and P val-
ues were assigned to each set of target spots. Gains and losses in DNA
copy number of given genes were determined as Cy5/Cy3 ratios of the
corresponding spots with higher than 1.5 and lower than 0.75, respec-
tively. For gene expression proﬁles, the upregulation and downregula-
tion of expressed genes were considered as Cy5/Cy3 ratios of the
corresponding spots with higher than 2.0 and lower than 0.5, respec-
tively. All ratios were ﬁltered by P value or a probability for an indi-
vidual set of target spots as part of the normal distribution. Only
those samples with P values of 0.01 or less were displayed in this pres-
ent work. DNA copy number changes involving whole sex chromo-
somes were not included in the analysis. All data are accessed and
available by our website http://202.127.18.238/CGH/.
2.8. Real-time PCR
To evaluate the correlation between genomic aberrations and tran-
scriptional levels, real-time PCRwere employed to detect theDNA copy
numbers and transcripts of some genes as the previously described [25].
The primers and probes for osteopontin (SPP1) and transgelin 2 as well
as b-actin as control were designed using Primer Express Sequence De-
sign Software (Invitrogen, Shanghai, China). The primers and probes
are listed as following: SPP1 for genomic DNA: forward, 5 0-
TTGTGCCGTGATTCAGTACC-30; reverse, 5 0-GGTTTCAGCACT-
CTGGTCAT-3 0; probe, 5 0-fam-AGGACCTGAACGCGCCTTCT-
GAT-tamra-30. SPP1 for transcript: forward, 5 0-AAGTTTCGC-
AGACCTGACAT-3 0; reverse, 5 0-GGTTTCAGCACTCTGGTCAT-
3 0; probe, 5 0-fam-AGGACCTGAACGCGCCTTCTGAT-tamra-30.
Transgelin 2 for genomic DNA: forward, 5 0-CTGTCCAAGAAGG-
GATTTA-30; reverse, 5 0-CCCATCTGTAACCCGATCAC-3 0; probe,
5 0-fam-TCCTCGGAACTTCTCGGATAACCA-tamra-3 0; Transgelin
2 for transcript: forward, 5 0-CCAACTGGTTCCCTAAGAAATC-30;
reverse, 5 0-CCCATCTGTAACCCGATCAC-3 0; probe, 5 0-fam-
TCCTCGGAACTTCTCGGATAACCA-tamra-3 0. In this present
work, cDNAwas synthesized in a 20 ll reaction systemwith 20 pmol oli-
go-dT as primer, in which 2 lg total RNA with DNase I treatment was
used as template. After incubated at 70 C for 5 min, the reaction was
mixed with 4 ll of 5· buﬀer, 2 ll of 0.1 M DTT, 2 ll dNTP (10 mM)
and 1 ll (200 U) SurperScript II reverse transcriptase (Invitrogen, Carls-
bad, CA) for further incubation at 42 C for 2 h. Real-time PCRs were
performed by TaqMan ABI 7700 (Applied Biosystems, Foster, Califor-
nia) in 25 ll reaction system, which contains 1 ll Hotstar Taq DNA
polymerase (Qiagen Valencia, CA, USA), 200 nM forward and reverse
primers each, and 1 ng of DNA or cDNA template, under thermal cy-
cling conditions as follows: pre-denature at 94 C for 15 min; denature
at 94 C, annealing at 55 C, and extend at 72 C for 40 s respectively.3. Results and discussion
3.1. The chromosomal pattern of genomic DNA copy number
alterations in HBV-induced HCC
In this present work, a total of 41 HCC specimens infected
by HBV were analyzed through the homemade cDNA micro-
array-based CGH, which contains PCR products representing
the sequenced 13824 genes/ESTs clones derived from the
HCC, liver, bone marrow, cord blood and neuroendocrine
[21,26,27]. Among 41 HCC specimens tested, the average num-
ber of target genes/ESTs with signiﬁcantly genomic DNA copy
number changes in each sample was 2596 ± 1185 (±S.D.), of
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Fig. 1. The chromosomal pattern of genome-wide DNA copy number alterations in HCC specimens. The pattern was here described based on 342 genes/ESTs with allelic ampliﬁcation and 360 with
allelic deletion occurred in more than 30% of 41 patients with HCC. Red and green bars represent the allelic ampliﬁcation and deletion of given genes/ESTs, respectively; and whilst, the length of bars
indicated the percentage of the HCC specimens with the gain or loss of a given gene/EST, where the scale was showed in upper right.
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Fig. 2. Histogram for the number of genes/ESTs with genomic DNA copy number alterations on diﬀerent chromosomal arms. The upper red bars
represent the number of genes/ESTs on certain chromosomal arms, which were based on 342 genes/ESTs with allelic ampliﬁcation in 41 HCC
specimens; whereas the below green bars indicated the number of genes/ESTs on certain chromosomal arms, based on 360 genes/ESTs with allelic
deletion in the same specimens. **P < 0.01; *P < 0.05 (v2 test).
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according to the stringent criteria with Cy5/Cy3 ratios of high-
er than 1.5 for gains and lower than 0.75 for losses. Further-
more, 342 genes/ESTs with allelic ampliﬁcation and 360 with
allelic deletion occurred in more than 30% of those 41 HCC
specimens (Fig. 1). The distribution of diﬀerent chromosomal
loci with genomic DNA aberrations, represented by those
genes/ESTs, indicated that the gains of genomic DNA copy
numbers were frequently observed on some certain chromo-
somal arms, such as 1q, 6p, 8q, 9p, and 10q, whereas the losses
of alleles, monoallele or bi-alleles, were often found on chro-
mosomes 1p, 16q, 17q and 19p (Figs. 1 and 2). In general,
the resulting data was consistent with the conventional meta-
phase-based CGH analyses on HCC specimens [28–30].
The microarray-based CGH can disclose the genomic aber-
rations in a higher resolution than the conventional CGH, in
which more genomic abnormalities were clustered onto certain
chromosomal subdomains. For example, genomic DNA copy
numbers on chromosomes 1q22-23, 1q25, 1q43, 2p13, 2p23,
2q11-21, 4q21, 4q28, 5q11-13, 6p21-25, 6q13, 8q11, 8q21,
8q24, 9p21-24, 10q25-26,11p15, 12p15, 13q14, 14q11, 15q22,
17q25 and 22q12-13 appeared to be frequently ampliﬁed in
these HCC specimens infected by HBV, whereas those mono-
allele or bi-alleles localized on chromosomes lp13-22, 1p32,
1p35-36, 2q33, 3q22-25, 4q32-35, 5q33, 8p11-21, 9q21,
10q11, 11q13, 12p13, 12q22, 14q24, 14q32, 15q11, 15q26,
16p11-12, 16q22, 16q23, 17p11, 17p13, 18q11-12, 19p13.2-
13.3, 19q13.2 and 19q13.3, could be in common deleted during
the hepatocarcinogenesis. Although some genomic DNA aber-
rations were diﬃcult to be ﬁne mapped onto chromosomal
subdomains in high-resolution manner due to the limited gene
clones and/or possibly large-scale genomic abnormalities, these
data would provide valuable information for identifying the
potential oncogenes and tumor suppressor genes associated
with HCC.
Recently, some evidences revealed that there are genomic
DNA copy number polymorphisms in diﬀerent individual hu-
man genome [31]. To evaluate whether the DNA copy num-
ber polymorphisms of individuals could be correlated with
the genomic alteration of those HCC specimens, six pairs
of HCC and the adjacent noncancerous livers were here em-
ployed to test their DNA copy number changes by the samearray-CGH. The resulting data indicated that the DNA copy
number changes of the noncancerous livers are distinct from
that of the corresponding HCC samples (correlation coeﬃ-
cient R2 < 0.01) (Fig. 3), implying that the ‘‘normal’’ poly-
morphisms in individuals could not be associated the
genomic DNA copy number alterations in HCC. In addition,
it is known that about 20% of adult liver cells are polyploidy.
To further evaluate the eﬀect of ‘‘normal’’ polyploidy on the
CGH results from HCC specimens, two adult livers from pa-
tients with haemangioma were also analyzed by the same ar-
ray CGH. The resulting data reﬂected that the genomic
pattern of ‘‘normal’’ polyploidy in those two individuals
could not be correlated with that of all HCC specimens (data
not shown). These data suggested that HBV-associated
hepatocarcinogenesis could be triggered by unique genetic
mechanisms that need to be further clariﬁed.
3.2. Relationship between genomic DNA copy number changes
and clinicopathologic features
To investigate the correlation between the genomic DNA
copy number aberrations and clinicopathologic features, sta-
tistical analysis was performed on the available clinical infor-
mation, including age, gender, clinical stages, pathological
and laboratory examinations in these 41 patients with HCCs.
However, the resulting data showed that no clinicopatho-
logic features were signiﬁcantly correlated with certain
chromosomal loci with genomic DNA copy number altera-
tions.
3.3. Correlation between genomic DNA copy number changes
and transcriptional levels
To evaluate the relationship between genomic DNA copy
number aberrations and transcriptional expression levels, we
further employed the same cDNA microarray to ﬁgure out
the gene expression proﬁles of 20 HCC specimens and avail-
able HCC cell lines, and then compared the gene expression
proﬁles with the corresponding genomic DNA copy number
changes (Fig. 4). Herein, the cDNA microarray-based CGH
exhibit the unique merit that can simultaneously address both
genomic DNA copy number changes and transcriptional
expression, but BAC array-based CGH assay is diﬃcult to de-
tect the gene expression although it may provides accurate
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Fig. 4. Comparison of array-based CGH data and gene expression proﬁl
performed on those paired data of array-based CGH data with genomic D
specimens (A) and 12 HCC cell lines (B). The correlation coeﬃcients (R2) w
alterations (left) and the corresponding transcriptional levels (right) of those
R2=           0.001                  0.003                0.007   0.002                 0.006                 0.0038  
C17    N17    C18    N18   C21    N21   C22    N22    C29    N29 C51   N51
Fig. 3. Comparison of array-based CGH data between HCC (C) and
non-cancerous livers (N). To evaluate correlation between the DNA
copy number polymorphisms of individuals and the genomic alteration
of those corresponding HCC specimens, six pairs of HCC and the
adjacent noncancerous livers were here employed to test their DNA
copy number changes by the same array-CGH. The correlation
coeﬃcients (R2) (below) were calculated by the comparison of the
genomic DNA copy number alterations in tumors (left) and the
corresponding non-tumor livers (right).
3576 J. Huang et al. / FEBS Letters 580 (2006) 3571–3581high-resolution chromosomal mapping. Interestingly, the
genomic DNA copy number aberrations appeared not to be
parallel with the corresponding gene expression proﬁles in
any given samples, whatever in HCC specimens or cell lines,
implying that the genomic DNA copy number alterations,
ampliﬁcation and loss, could not be crucial to the transcrip-
tional expression of most genes in HCC. In other words, the
transcriptional levels of these genes were regulated by many
molecular mechanisms, including genetic and epigenetic fac-
tors and networks, although the previous study showed that
62% of highly ampliﬁed genes demonstrated moderately or
highly elevated expression [14].
However, a few genes with genomic DNA copy number
aberrations indeed exhibit the dysregulation of gene expres-
sion, implying that the deregulated genes could be partially rel-
ative to the DNA copy number changes. Among them, the
transcriptional levels of few known important genes with
genomic DNA copy number alterations, gains or losses, was
deregulated at transcriptional levels in HCC specimens (Table
2). For example, the genomic DNA copy numbers of both se-
creted phosphoprotein 1 (osteopontin) (SPP1) and paternally
expressed 10 (PEG 10) were signiﬁcantly ampliﬁed, partially
in consistency with the upregulated transcripts in HCC
(Fig. 5), where these two genes were known to be highly ex-
pressed in hepatocarcinogenesis [32,33]. Similarly, transgelin
2 (TAGLN2), H2A histone family, member L (HIST1H2AC),
importin 9 (IPO9), and attractin-like 1 (ATRNL1) also exhib-
ited the increasing genomic DNA copy numbers and upregu-
lated transcripts in HCC, implying that the genes could be
involved in hepatocarcinogenesis. In contrast, more genes,B
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Table 2
Some genes with genomic DNA copy number alterations and deregulated expression
Gene Name Description UniGene Chromosomes DNA RNA
Number
(%)a
Status Number
(%)b
Status
SPP1 secreted phosphoprotein 1 (osteopontin) Hs.313 4q21-q25 18 (43.9) gain 15 (75.0) UP
TAGLN2 transgelin 2 Hs.75725 1q21-q25 25 (61.0) gain 12 (60.0) UP
PEG10 paternally expressed 10 Hs.137476 7q21 16 (39.5) gain 9 (45.0) UP
PPIB peptidylprolyl isomerase B (cyclophilin B) Hs.699 15q21-q22 28 (68.3) gain 8 (40.0) UP
AKR1C3 aldo-keto reductase family 1, member C3 Hs.78183 10p15 30 (73.2) gain 7 (35.0) UP
H2AFL H2A histone family, member L Hs.28777 6p21.3 22 (53.7) gain 6 (30.0) UP
TBPL1 TBP-like 1 Hs.13993 6q22.1-q22.3 16 (39.0) loss 16 (80.0) DOWN
NTN4 netrin 4 Hs.102541 12q22-q23 27 (65.9) loss 13 (65.0) DOWN
ZNF313 zinc ﬁnger protein 313 Hs.10590 20q13.13 29 (70.7) loss 13 (65.0) DOWN
LRMP lymphoid-restricted membrane protein Hs.40202 12p12.3 24 (58.5) loss 13 (65.0) DOWN
MRC1 mannose receptor, C type 1 Hs.75182 10p13 30 (73.2) loss 12 (60.0) DOWN
NR4A1 nuclear receptor subfamily 4, group A, member 1 Hs.1119 12q13 16 (39.0) loss 12 (60.0) DOWN
AADAC arylacetamide deacetylase (esterase) Hs.587 3q21.3-q25.2 20 (48.8) loss 11 (55.0) DOWN
TGFBR3 transforming growth factor, beta receptor III Hs.342874 1p33-p32 22 (53.7) loss 10 (50.0) DOWN
SDC4 syndecan 4 (amphiglycan, ryudocan) Hs.252189 20q12 28 (68.3) loss 10 (50.0) DOWN
SLC27A2 solute carrier family 27 (fatty acid transporter), member 2 Hs.11729 15q21.2 15 (36.6) loss 10 (50.0) DOWN
PTPRC protein tyrosine phosphatase, receptor type, C Hs.170121 1q31-q32 17 (41.5) loss 9 (45.0) DOWN
SORL1 sortilin-related receptor Hs.278571 11q23.2-q24.2 14 (34.1) loss 9 (45.0) DOWN
ITPR2 inositol 1,4,5-triphosphate receptor, type 2 Hs.238272 12p11 14 (34.1) loss 9 (45.0) DOWN
ESRRA estrogen-related receptor alpha Hs.110849 11q13 14 (34.1) loss 9 (45.0) DOWN
GAP43 growth associated protein 43 Hs.79000 3q13.1-q13.2 15 (36.6) loss 8 (40.0) DOWN
HSCARG HSCARG protein Hs.288969 16p13.3 16 (39.0) loss 7 (35.0) DOWN
GPX3 glutathione peroxidase 3 (plasma) Hs.336920 5q23 27 (65.9) loss 7 (35.0) DOWN
aIndicated the numbers of patients with the genomic DNA copy number alterations of a given gene through the array-based CGH analysis on 41
HCC specimens.
bIndicated the numbers of patients with deregulated expression of a given gene through the same microarray analysis on 20 HCC specimens.
J. Huang et al. / FEBS Letters 580 (2006) 3571–3581 3577including transforming growth factor, beta receptor III
(TGFBR3), lymphoid-restricted membrane protein (LRMP),
mannose receptor, C type 1 (MRC1), estrogen-related receptor
alpha (ESRRA), MLL, carcinoembryonic antigen-related cell
adhesion molecule 6 (CEACAM6), cellular repressor of
E1A-stimulated genes (CREG), growth associated protein
43, vitamin D-binding protein (GC), sortilin-related receptor
(SORL1), and MEG3, showed the decreasing DNA copy num-
bers and downregulated transcriptional levels in certain HCC
specimens, suggesting that the genetic abnormalities of these
genes could partially contribute to hepatocarcinogenesis.
Interestingly, some genes with unknown functions also exhibit
similar features, which should be further investigated on the ef-
fect on oncogenesis of HCC.
3.4. DNA ampliﬁcation of osteopontin (SPP1) on chromosome
4q21 could partially contribute to the upregulated transcript
Loss of heterozygosis (LOH) involving chromosome 4q was
frequently observed in HCC and various cancers, such as
breast cancer [34], oral squamous cell carcinomas [35] prostate
cancer [36] and gastric carcinomas [37]. However, the ampliﬁ-
cation of DNA copy number of some loci on chromosome
4q21 and 4q28 was here found (Fig. 1), which the chromo-
somal gain on 4q was ﬁrst reported. Interestingly, osteopontin
(SPP1), which is a member of the SIBLING family that plays
an important role in tumor development, invasion and metas-
tasis through integrating signaling events [38,39], was located
on chromosome 4q21. It is known that SPP1 was signiﬁcantly
upregulated in HCC with metastasis [32]. Herein, the ampliﬁ-
cation of genomic DNA copy number of the gene was detected
in 43.9% (18/41) patients with HCC through array-based
CGH, and whilst the transcript was upregulated in 75% (15/20) HCC specimens (Table 2), where both DNA ampliﬁcation
and upregulation of transcript were simultaneously found in 6
cases (Fig. 5A), implying that the genomic DNA ampliﬁcation
of SPP1 could partially contribute to the upregulated tran-
script although the multiple molecular mechanisms also could
be involved in the process.
To independently evaluate the correlation between the
ampliﬁcation and upregulation of SSP1, real-time PCR was
carried out to determine genomic DNA copy number and tran-
scriptional levels in 38 pairs of HCC specimens and corre-
sponding non-HCC livers, where b-actin was used as a
reference. The resulting data showed that the genomic DNA
copy number of the gene was ampliﬁed in 55.3% (21/38)
HCC specimens (Fig. 5B), which are generally parallel with
the data from microarray-based CGH although real-time
PCR seem to be more sensitive, implying that the micro-
array-based CGH data is reliable and valuable for profound
understanding of genetic mechanisms involved in HCC. More-
over, the transcriptional upregulation of the gene was found in
76.3% (29/38) HCC specimens, including two samples with
invasion (03_16 C and ZS_30 C) (Fig. 5B), where both geno-
mic DNA ampliﬁcation and transcriptional upregulation were
simultaneously observed in 39% (15/38) HCC specimens,
implying that the transcriptional upregulation of the gene
could only be partially ascribed to the DNA ampliﬁcation be-
cause there are complex genetic and epigenetic mechanisms
were involved in the hepatocarcinogenesis. For example, previ-
ous studies showed that transcript of SSP1 is regulated by
numerous transcription factors, including RRF, Sp1, Myc
and Oct-1 [40]. As the previous studies suggested, SPP1 could
be a potential molecular diagnostic marker and become opti-
mal molecular targets for novel therapies for various cancers
3578 J. Huang et al. / FEBS Letters 580 (2006) 3571–3581[32]. Herein, HCC specimens with genomic DNA ampliﬁcation
and overexpression of SPP1 indeed exhibited diﬀerent patho-
logical stages and tumor sizes. However, whether the genomic
DNA ampliﬁcation of SPP1 is an earlier event during hepato-
carcinogenesis or is involved in tumor progression should be
further investigated.
3.5. TAGLN2 involving chromosome 1q21 in HCC
As known, chromosome 1q gain is also one of the most
common chromosomal aberrations in HCC, although the
accurate genetic abnormalities during hepatocarcinogenesis
are still unclear. In the present study, the high incidences
of gains at multiple loci on chromosome 1q, including
chromosome 1q21-23, 1q24-25, 1q32 and 1q43, were ob-
served in these HCC specimens (Fig. 1). Compared with
gene expression proﬁles, we paid attention on the upregu-
lated TAGLN2 involving chromosome 1q21 with genomicR
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where b-actin was used as reference.DNA ampliﬁcations (Fig. 5C), although genomic DNA
ampliﬁcation of CD1b, MNDA and SDHC localized on
the same chromosomal region was also observed in some
HCC specimens without the signiﬁcantly upregulated tran-
scripts of these genes. It is known that TAGLN2 was in-
volved in cell proliferation and migration [41]. To further
evaluate the genetic aberration and transcriptional level of
TAGLN2, the real-time PCR was also employed to detect
the genomic DNA copy number and transcriptional level.
The resulting data showed that DNA ampliﬁcations of
TAGLN2 occurred in 36.1% (13/36) HCC samples, and
whilst the overexpression of transcript was found in 63.9%
(23/36) HCC. However, both DNA ampliﬁcation and over-
expression of the gene were only found in 28% (10/36)
HCC specimens (Fig. 5D), implying that the overexpression
of TAGLN2 could only be partially ascribed to the DNA
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J. Huang et al. / FEBS Letters 580 (2006) 3571–3581 3579involved in the upregulation of TAGLN2. In addition, some
reports indicated that TAGLN2 was also overexpressed in
gastric cancer [34] and HCC [42], where TAGLN2 was even
considered as a diagnostic marker for HCC. However, very
little is known about the actual eﬀect of TAGLN2 on
hepatocarcinogenesis and tumor progress. Whether chromo-
some 1q21-25 ampliﬁcon involving TAGLN2 as an impor-
tant event could contribute to HCC should be further
clariﬁed.
Furthermore, PEG 10 localized on chromosome 7q21 was
evaluated in HCC specimens (Fig. 5E and F). The ampliﬁca-
tion of genomic DNA copy number of the gene was detected
in 39.0% (16/41) HCC specimens through array-based CGH,
and whilst the transcript was upregulated in 45% (9/20) HCC
specimens (Table 2), where both DNA ampliﬁcation and
upregulation of transcript were simultaneously found in 6
cases (Fig. 5E), implying that the genomic DNA ampliﬁcation
of SPP1 could partially contribute to the upregulated tran-
script although there might be multiple molecular mechanisms
in the upregulation. RT-PCR experiments also conﬁrmed that
the upregulation of PEG 10 was found in another 67% (20/30)HCC specimens (Fig. 5F), implying that the overexpression of
the gene could be an important event in oncogenesis of HCC,
which also need to be further investigated.
In conclusion, this present work employed cDNA micro-
array-based CGH assay to ﬁgure out chromosomal patterns
with the genomic DNA copy number aberrations in a high-
resolution through examining 41 HCC specimens. Moreover,
the comparison of genomic DNA copy number alterations
and the transcriptional expression in the same 20 HCC speci-
mens and 12 HCC cell lines provided new insights into hepato-
carcinogenesis and the feasibility to identify potential novel
oncogenes or tumor suppressor genes associated with HCC
through integrating array-based CGH data with gene expres-
sion proﬁles. In addition, we also address the genomic aberra-
tions and deregulatory transcripts of SPP1, TAGLN2 and
PEG10 as examples that could contribute to hepatocarcino-
genesis and tumor progress.
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